Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | CCR2 | P41597 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.43 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29268969 | 0.87 | NPC1 (0.55) | SMN1; SMN2KMT2APOLBMAPTNPC1 | |
| SCHEMBL364174 | 0.84 | NPC1 (0.62) | SMN1; SMN2KMT2ANPC1RAB9ANAMPT | |
| SCHEMBL8180075 | 0.84 | NPC1 (0.60) | SMN1; SMN2KMT2APOLBMAPTNPC1 | |
| Water SCHEMBL30838095 | 0.83 | NPC1 (0.60) | SMN1; SMN2KMT2ANPC1RAB9ANAMPT | |
| SCHEMBL6639389 | 0.82 | RAB9A (0.61) | SMN1; SMN2NPC1RAB9ACTDSP1PTGS2 | |
| SCHEMBL854076 | 0.81 | NAMPT (0.49) | NPC1RAB9ACTDSP1PTGS2NAMPT | |
| SCHEMBL633936 | 0.78 | NAMPT (0.61) | SMN1; SMN2KMT2ANPC1RAB9ANAMPT | |
| SCHEMBL29167802 | 0.78 | NAMPT (0.61) | SMN1; SMN2KMT2ANPC1RAB9ANAMPT | |
| SCHEMBL13868569 | 0.78 | NAMPT (0.61) | SMN1; SMN2KMT2ANPC1RAB9ANAMPT | |
| SCHEMBL10557090 | 0.77 | CARM1 (0.52) | KMT2ANPC1RAB9AMEN1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115916771-A | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115916771-A | Multi-target antitumor compound and preparation method and application thereof | 浙江华海药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | IGNYTA, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200163892-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | IGNYTA, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| EP-3227276-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA | Ignyta, Inc. (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | IGNYTA, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3107541-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | Ignyta, Inc. (US) | 2016-12-28 | — | — | EP | disclosed |
| WO-2016089760-A1 | COMBINATIONS FOR THE TREATMENT OF NEUROBLASTOMA | IGNYTA, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2015124697-A1 | COMPOUNDS FOR TREATING PATIENTS WITH ROS1 MUTANT CANCER CELLS | IGNYTA, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| EP-0885890-A1 | SULFONYLUREIDOPYRAZOLE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007599-A1 | METHODS FOR TREATING NEUROBLASTOMA | NEK2, CSNK1G3, AHNAK | SMN1; SMN2 58/4885KMT2A 802/4885POLB 2806/4885 |
| US-20200163892-A1 | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | SMN1; SMN2 633/4885KMT2A 604/4885POLB 2988/4885 |
| US-11253515-B2 | Pharmaceutical compositions and dosage forms | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PAICS | SMN1; SMN2 633/4885KMT2A 604/4885POLB 2988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.